home.aspx
 
. https://www.biospace.com/article/as-pandemic-continues-rafael-pharmaceuticals-enrolls-patients-in-phase-iii-pancreatic-cancer-trial-/
article
SHARESHARESHARE
AS PANDEMIC CONTINUES, RAFAEL PHARMACEUTICALS ENROLLS PATIENTS IN PHASE III PANCREATIC CANCER TRIAL
That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute. READ MORE